VERU Profile
Veru Inc (VERU) is a pharmaceutical company that develops and commercializes medicines for the management of urological and oncological diseases. The company is headquartered in Miami, Florida, and was founded in 2013.
Veru's product portfolio includes prescription drugs and over-the-counter products for urology and oncology. The urology products include Tadalafil and Solifenacin, while the oncology products include Zuclomiphene Citrate and Sabizabulin.
The company's Tadalafil tablet is used to treat benign prostatic hyperplasia (BPH), erectile dysfunction (ED), and pulmonary arterial hypertension (PAH). Solifenacin is an antimuscarinic agent that is used to treat overactive bladder.
Zuclomiphene Citrate is being developed to treat hot flashes in men undergoing hormone therapy for prostate cancer. Sabizabulin, a novel anti-tubulin agent, is being developed as a treatment for metastatic castration-resistant prostate cancer and other malignancies.
In addition, Veru offers a suite of urology products that are sold over-the-counter, including PREBOOST and FC2 Female Condoms.
The company's stock is traded on the NASDAQ Global Market under the ticker symbol "VERU".
|
